Italfarmaco has acquired 100% of Lacer Pharmaceuticals, one of the leading companies in Spain in the health and personal care segment.
With over 70 years of experience, a turnover of more than EUR 150 million in 2021 and almost 500 employees, Lacer is one of the market leaders in almost every segment in which it operates, particularly in the oral and dental area with the Lacer brand and brands such as Thrombocid, Pilexil, Anso and Talquistine. Lacer also has an extensive portfolio of drugs in the cardiovascular and urogynecological areas.
Italfarmaco, with this acquisition, strengthens its footprint in the Spanish healthcare market where it is already operating with well-known brands and consolidates its current business units in which it has been active successfully for over 30 years in Italy and worldwide.
In addition, by incorporating the Lacer production plant in Cerdanyola del Valles, Italfarmaco, which already has five production sites, will add an asset to the Group’s industrial activities.
The integration into Italfarmaco will allow Lacer to consolidate its position in Spain by actively investing in its existing brands and expanding its product portfolio, both in the healthcare sector and in the Prescription Medicines division. Furthermore, Lacer will benefit from Italfarmaco’s global sales network of subsidiaries and distributors to increase its growth internationally.
Linklaters advised Italfarmaco on the acquisition of a 100% stake of Lacer with Alejandro Ortiz (pictured left, above), José María López (pictured right above) and Ignacio Moreno.
KPMG Abogados also advised Italfarmaco. The firm has performed the tax due dilligence of the target group, tax advice on the pre-deal carve-out transactions and the review of SPA tax clauses. The KPMG Abogados team was led by Fernando Gómez Galicia (partner pictured below) and Jacobo de la Guardia (senior manager).
Lacer has been advised by DWF-RCD with a team led by Oscar Alegre (pictured below).